Browsing Category

Features

1035 posts

Debate on Drug Pricing Reforms Takes a New Turn
By

By
Congress is debating several proposed legislative measures on drug pricing. A key point of debate is what role should global pricing have in setting drug pricing in the US. What…

HPAPI Mfg: The Market Drivers and CDMO/CMO Expansions
By

By
High-potency active pharmaceutical ingredient (HPAPI) manufacturing continues to be an active area of investment by CDMOs/CMOs. DCAT Value Chain Insights analyzes key market drivers, including for antibody drug conjugates and other oncology…

The EU: Next Steps in Policy Reforms in Drug Manufacturing and Supply
By

By
As part of its Pharmaceutical Strategy for Europe, the European Commission has put out a public consultation, which will be open to December 21, to gather views from stakeholders and…

Bio/Pharma M&A: Which Companies are Leading Deals in 2021?
By

By
What have been the leading mergers and acquisitions among bio/pharmaceutical companies thus far in 2021? What is the strategy behind the deals, and which companies are seeking to target the…

Strategy Focus: Big Pharma and Rare Diseases
By

By
AstraZeneca’s $39-billion acquisition of Alexion Pharmaceuticals earlier this year was yet another move by a large bio/pharmaceutical company to strengthen its portfolio in drugs to treat rare diseases. What are…

Global Bio/Pharma Watch: Geographic Market Performance
By

By
What are the key happenings in the global bio/pharmaceutical industry from a market perspective? DCAT Value Chain Insights provides a view of key developments from across the globe impacting growth and industry…

The Pharma Pulse: Precision Medicine and Manufacturing
By

By
What may the future hold for manufacturing lower-volume drugs created by personalized medicines and more targeted therapies? Are smaller batch runs simply the answer or how may manufacturing evolve to…

The EU: Manufacturing and Preparing for the Next Health Emergency
By

By
The European Commission has launched the European Health Emergency preparedness and Response Authority (HERA) for ensuring the development, production and distribution of medicines, vaccines and other medical countermeasures in health…

President Biden Announces Plan for Drug-Pricing Reform
By

By
President Joe Biden has released a plan for drug-pricing reform in the US. One of the key measures is to allow the federal government to negotiate drug prices under Medicare,…

CDMOs Invest in Biomanufacturing, Cell- & Gene-Therapy Manufacturing
By

By
Biomanufacturing is an active area of investment by CDMOs with several large expansions by Samsung Biologics, Fujifilm Diosynth, Boehringer Ingelheim, and Lonza. Other CDMOs (Catalent, Thermo Fisher, WuXi AppTec, AGC…